Trial · NCT03446612
Outcomes53
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
21 to 40 of 53
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to 59 days | Safety Population includes all randomised participants who received at least one dose of study treatment. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Any AE of Special Interest (AESI) | Up to 59 days | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Discontinuing the Randomized Study Treatment | Up to Day 42 | Safety Population | Participants | COUNT_OF_PARTICIPANTS |
| OTHER_PRE_SPECIFIED | Absolute Values of Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) | Days 1, 14, 28, 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | millimeters of mercury (mmHg) | MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline in DBP and SBP | Baseline (Day 1) and at Days 14, 28, 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | mmHg | MEAN |
| OTHER_PRE_SPECIFIED | Absolute Values of Electrocardiogram (ECG) Mean Heart Rate | Days 1, 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Beats per minute | MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline in ECG Mean Heart Rate | Baseline (Day 1) and at Days 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Beats per minute | MEAN |
| OTHER_PRE_SPECIFIED | Absolute Values of ECG Parameters- PR Interval, QRS Interval, and QT Interval and QT Interval Corrected for Heart Rate Using Bazett's Formula (QTcB) | Days 1, 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Milliseconds | MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline in ECG Parameters- PR Interval, QRS Duration, and QT Interval and QTcB | Baseline (Day 1) and at Days 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Milliseconds | MEAN |
| OTHER_PRE_SPECIFIED | Absolute Values of the Hematology Parameters of Platelet Count, White Blood Cell (WBC) Count (Absolute), Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils | Days 1, 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Giga cells per Liter | MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline in Hematology Parameters of Platelet Count, Leukocytes, Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils | Baseline (Day 1) and at Days 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Giga cells per Liter | MEAN |
| OTHER_PRE_SPECIFIED | Absolute Values of the Hematology Parameter of Red Blood Cell (RBC) Count and Reticulocyte Count (RC) | Days 1, 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Trillion cells per liter | MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline in Hematology Parameters of RBC Count and RC | Baseline (Day 1) and at Days 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Trillion cells per liter | MEAN |
| OTHER_PRE_SPECIFIED | Absolute Values of the Hematology Parameters of Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) | Days 1, 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Grams per deciliter | MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline in Hematology Parameters- Hemoglobin and MCHC | Baseline (Day 1) and at Days 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Grams per deciliter | MEAN |
| OTHER_PRE_SPECIFIED | Absolute Values of Hematology Parameter: Hematocrit | Days 1, 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Proportion of red blood cells in blood | MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline in Hematology Parameter: Hematocrit | Baseline (Day 1) and at Days 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Proportion of red blood cells in blood | MEAN |
| OTHER_PRE_SPECIFIED | Absolute Values of Hematology Parameter of Red Blood Cell Distribution Width (RDW) | Days 1, 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Percentage of width | MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline in RDW | Baseline (Day 1) and at Days 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Percentage of width | MEAN |
| OTHER_PRE_SPECIFIED | Absolute Values of the Hematology Parameter of Mean Corpuscular Hemoglobin (MCH) | Days 1, 42 and 59 | Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Picograms | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03446612/outcomes?page=2